v3.26.1
Collaboration and License Agreements - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2024
Dec. 31, 2025
Mar. 29, 2024
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Revenue recognized $ 0 $ 959 $ 0 $ 2,877        
Deferred revenue 0 0 0 0 $ 2,877 $ 0    
Accounts receivable $ 0 0 $ 0 0 443 $ 0    
Pfizer, Inc. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Material transfer and evaluation agreement initial period 2 years 6 months   2 years 6 months          
Pfizer, Inc. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Transferred over Time [Member]                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Deferred Revenue, Revenue Recognized $ 0 0 $ 0 400        
Contract with Customer, Liability, Current               $ 1,000
Contract with Customer Transaction Price         $ 1,900      
Janssen Pharmaceutica NV                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Revenue recognized   $ 1,000   $ 2,500        
Janssen Pharmaceutica NV | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Additional milestone payments receivable     $ 839,000          
Janssen Pharmaceutica NV | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Up-front Payment                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Contract with Customer, Liability, Current             $ 6,500